SITE007-0298

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2023-02-12

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-23 (study day 51); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-11 (study day 222); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-16 (study day 350); relationship: not assessed

severe serious assessed

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-04-19 (study day 413); relationship: N; serious criteria: hospitalization

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-05-08 (study day 432); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-08-27 (study day 543); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-10-17 (study day 594); relationship: N

Data queries

No data queries.